Steve Butts, Arrivo BioVentures CEO

Ar­ri­vo bags $45M Se­ries B to fund ma­jor de­pres­sion late-stage test and PhII-ready pan­cre­ati­tis as­set

Ar­ri­vo BioVen­tures has closed an over­sub­scribed $45.25 mil­lion Se­ries B fundraise with an eye to progress its pipeline through the next stage of tri­als, in­clud­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.